T. Rowe Price Associates’s Novo Nordisk NVO Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $428M | Buy |
6,203,264
+878,598
| +17% | +$60.6M | 0.05% | 295 |
|
|
2025
Q1 | $370M | Sell |
5,324,666
-1,020,452
| -16% | -$70.9M | 0.05% | 314 |
|
|
2024
Q4 | $546M | Sell |
6,345,118
-3,238,317
| -34% | -$279M | 0.06% | 254 |
|
|
2024
Q3 | $1.14B | Buy |
9,583,435
+79,671
| +0.8% | +$9.49M | 0.13% | 150 |
|
|
2024
Q2 | $1.36B | Buy |
9,503,764
+914,542
| +11% | +$131M | 0.16% | 124 |
|
|
2024
Q1 | $1.1B | Buy |
8,589,222
+823,036
| +11% | +$106M | 0.14% | 157 |
|
|
2023
Q4 | $803M | Sell |
7,766,186
-464,729
| -6% | -$48.1M | 0.11% | 183 |
|
|
2023
Q3 | $749M | Buy |
8,230,915
+4,403,470
| +115% | +$400M | 0.11% | 188 |
|
|
2023
Q2 | $619M | Buy |
3,827,445
+41,885
| +1% | +$6.78M | 0.09% | 221 |
|
|
2023
Q1 | $602M | Buy |
3,785,560
+3,551,104
| +1,515% | +$565M | 0.09% | 222 |
|
|
2022
Q4 | $31.7M | Buy |
+234,456
| New | +$31.7M | 0.01% | 793 |
|
|
2020
Q2 | – | Sell |
-356,798
| Closed | -$21.5M | – | 2526 |
|
|
2020
Q1 | $21.5M | Buy |
+356,798
| New | +$21.5M | ﹤0.01% | 1047 |
|